Exelixis (EXEL) Cost of Revenue (2013 - 2026)
Exelixis' (EXEL) quarterly Cost of Revenue came in at $20.0 million in Q2 2026, up 4.07% year-on-year from $19.2 million in Q2 2025, and down 24.65% quarter-over-quarter from $26.5 million in Q1 2026.
Exelixis (EXEL) Cost of Revenue (2013 - 2026) Analysis & Trends
Exelixis' Cost of Revenue history runs 14 years deep, the most recent figure standing at $20.0 million for Q2 2026.
- On a quarterly basis, Cost of Revenue rose 4.07% year-over-year to $20.0 million in Q2 2026; TTM through Apr 2026 was $84.5 million, a 13.96% increase from a year earlier, with the FY2026 full-year figure at $83.7 million, up 9.82% from the prior year.
- Cost of Revenue declined to $20.0 million in Q2 2026 per EXEL's latest filing, from $26.5 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $26.5 million in Q1 2026 and bottomed at $13.2 million in Q2 2022.
- The 5-year median for Cost of Revenue is $18.6 million (2025), against an average of $18.3 million.
- Across the five-year window, Cost of Revenue jumped 48.49% in 2024 and fell 9.8% in 2025, its largest moves.
- Year by year, Cost of Revenue stood at $15.9 million in 2022, then surged by 36.64% to $21.8 million in 2023, then declined by 20.34% to $17.3 million in 2024, then climbed by 7.19% to $18.6 million in 2025, then grew by 7.42% to $20.0 million in 2026.
- Per Business Quant, the three latest EXEL Cost of Revenue figures stand at $20.0 million (Q2 2026), $26.5 million (Q1 2026), and $18.6 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Exelixis | 14.44 Bn | 13.66 Bn | 590.86 Mn | 19.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 19.95 Mn |
| Apr 3, 2026 | 19.95 Mn |
| Jan 2, 2026 | 26.48 Mn |
| Jan 2, 2026 | 26.48 Mn |
| Oct 3, 2025 | 18.57 Mn |
| Oct 3, 2025 | 18.57 Mn |
| Jul 4, 2025 | 19.47 Mn |
| Jul 4, 2025 | 19.47 Mn |
| Apr 4, 2025 | 19.17 Mn |
| Apr 4, 2025 | 19.17 Mn |
| Jan 3, 2025 | 19.97 Mn |
| Jan 3, 2025 | 19.97 Mn |
| Sep 27, 2024 | 17.33 Mn |
| Sep 27, 2024 | 17.33 Mn |
| Jun 28, 2024 | 17.67 Mn |
| Jun 28, 2024 | 17.67 Mn |
| Mar 29, 2024 | 21.26 Mn |
| Mar 29, 2024 | 21.26 Mn |
| Dec 29, 2023 | 21.75 Mn |
| Dec 29, 2023 | 21.75 Mn |